文献速递临床试验与 GCP流行病学与生物统计

免疫肿瘤临床试验中同时纳入应答者与非应答者的设计策略

Design for immuno-oncology clinical trials enrolling both responders and nonresponders.
PubMed 文献 · Stat Med · 2020-09-17

免疫肿瘤(IO)试验的Kaplan-Meier曲线常出现非比例风险(NPH)模式,传统设计忽略此问题导致把握度不足或假阴性。本文提出PRIME策略,将治疗非应答者产生的二分类应答信息嵌入设计,可达到理想把握度,并量化非应答者对研究效率的影响。

要点

  • 传统设计忽略NPH模式,导致IO研究把握度不足或假阴性。
  • PRIME策略嵌入应答信息,可达到理想把握度。
  • PRIME策略通过纳入更多前瞻性应答者来缓解NPH模式。

核心结论

  • PRIME策略能正确纳入治疗非应答者产生的二分类应答信息,达到理想把握度。
  • 传统方法在存在NPH模式时导致严重把握度损失。
  • PRIME策略可量化治疗非应答者对研究效率的影响,并指导设计足够把握度的IO试验。

研究设计与样本

  • 文章通过经验性和解析性方法展示,在样本量不足的IO研究中治疗非应答者会产生多种NPH模式。
  • 提出并评估了一种新的设计与分析策略PRIME(P%-responder information embedded)。
  • 开发了R包Immunotherapy.Design用于实现该策略。

主要发现

  • 传统替代方法在存在NPH模式时导致严重把握度损失。
  • PRIME策略可达到理想把握度。
  • PRIME策略通过纳入更多前瞻性应答者来缓解NPH模式并提升研究效率。

临床怎么用

  • 在IO试验设计中应纳入应答信息以正确处理NPH模式,避免把握度不足。
  • 可使用PRIME策略量化非应答者对研究效率的影响,指导样本量设计。
  • 可通过纳入更多前瞻性应答者来提升研究效率并缓解NPH模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A typical challenge facing the design and analysis of immuno-oncology (IO) trials is the prevalence of nonproportional hazards (NPH) patterns manifested in Kaplan-Meier curves under time-to-event endpoints. The NPH patterns would violate the proportional hazards assumption, and yet conventional design and analysis strategies often ignore such a violation, resulting in underpowered or even falsely negative IO studies. In this article, we show, both empirically and analytically, that treating nonresponders in IO studies of inadequate size would give rise to a variety of NPH patterns; we then present a novel design and analysis strategy, P%-responder information embedded (PRIME), to properly incorporate the dichotomized response incurred from treating nonresponders. Empirical studies demonstrate that the proposed strategy can achieve desirable power, whereas the conventional alternative leads to a severe power loss. The PRIME strategy allows us to quantify the impact of treating nonresponders on study efficiency, thereby enabling a proper design of IO trials with an adequate power. More importantly, it pinpoints a solution to enhance the study efficiency and alleviates the NPH patterns by enrolling more prospective responders. An R package (Immunotherapy.Design) is developed for implementation.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Xu Z, Zhu B, Park Y, et al. Design for immuno-oncology clinical trials enrolling both responders and nonresponders. Stat Med. 2020. PMID: 32944979. doi:10.1002/sim.8694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。